DRKS00010069
Completed
Phase 3
Marker-based follow-up of patients with non muscle-invasive low/intermediate risk bladder cancer - UroFollow
Forschungsstiftung Medizin am Universitätsklinikum Erlangen0 sites210 target enrollmentMarch 22, 2016
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- pTa G1-2 bladder cancer
- Sponsor
- Forschungsstiftung Medizin am Universitätsklinikum Erlangen
- Enrollment
- 210
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Completely resected primary or recurrent bladder cancer low/intermediate risk NMIBC pTa G1\-2 with progression risk \<5% within 3 years of follow\-up, based on EORTC\-risk\-tables (Sylvester et al. 2006; http://www.eortc.be/tools/bladdercalculator); ECOG\-status 0\-2 (ambulatory, capable of self\-care)
Exclusion Criteria
- •Adjuvant BCG\-therapy;
- •Concomitant bladder carcinoma in situ;
- •Tumour size \>3 cm;
- •Participation in another oncological study;
- •Other cancers (except of cutaneous squamous or basal cell carcinoma) within the last 5 years;
- •Dialysis\-dependent renal insufficiency
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical TrialsSpinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]CTIS2024-511707-42-00ovartis Pharma AG160
Not yet recruiting
Phase 3
ong-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 in Clinical trialsJPRN-jRCT2033230642Hirano Takamitsu4
Active, not recruiting
Not Applicable
Risk-based identification of patients with musculoskeletal pain and individualized care pathway in primary healthcare (RETAR study) – a study protocol for a benchmarking controlled trialImproving outcomes in patients with musculoskeletal painMusculoskeletal DiseasesISRCTN59800706niversity of Oulu222
Recruiting
Phase 1
Clinical observation on recurrence of non muscle invasive bladder cancer by Nourishing Yin and Clearing Sourceon muscle invasive bladder cancerITMCTR2000003747Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Shanghai University of Traditional Chinese Medicine
Completed
Phase 4
A non-interventional biomarker study in patients with NSCLC of adenocarcinoma tumour histology eligible for treatment with Vargatef according to the approved labellung cancerNon small-cell lung carcinoma10029107NL-OMON46049Boehringer Ingelheim34